Genome-minimized Streptomyces Host for the Heterologous Expression of Secondary Metabolism
Overview
Affiliations
To construct a versatile model host for heterologous expression of genes encoding secondary metabolite biosynthesis, the genome of the industrial microorganism Streptomyces avermitilis was systematically deleted to remove nonessential genes. A region of more than 1.4 Mb was deleted stepwise from the 9.02-Mb S. avermitilis linear chromosome to generate a series of defined deletion mutants, corresponding to 83.12-81.46% of the wild-type chromosome, that did not produce any of the major endogenous secondary metabolites found in the parent strain. The suitability of the mutants as hosts for efficient production of foreign metabolites was shown by heterologous expression of three different exogenous biosynthetic gene clusters encoding the biosynthesis of streptomycin (from S. griseus Institute for Fermentation, Osaka [IFO] 13350), cephamycin C (from S. clavuligerus American type culture collection (ATCC) 27064), and pladienolide (from S. platensis Mer-11107). Both streptomycin and cephamycin C were efficiently produced by individual transformants at levels higher than those of the native-producing species. Although pladienolide was not produced by a deletion mutant transformed with the corresponding intact biosynthetic gene cluster, production of the macrolide was enabled by introduction of an extra copy of the regulatory gene pldR expressed under control of an alternative promoter. Another mutant optimized for terpenoid production efficiently produced the plant terpenoid intermediate, amorpha-4,11-diene, by introduction of a synthetic gene optimized for Streptomyces codon usage. These findings highlight the strength and flexibility of engineered S. avermitilis as a model host for heterologous gene expression, resulting in the production of exogenous natural and unnatural metabolites.
Design and regulation of engineered bacteria for environmental release.
Chemla Y, Sweeney C, Wozniak C, Voigt C Nat Microbiol. 2025; 10(2):281-300.
PMID: 39905169 DOI: 10.1038/s41564-024-01918-0.
When synthetic biology meets medicine.
Feng Y, Su C, Mao G, Sun B, Cai Y, Dai J Life Med. 2025; 3(1):lnae010.
PMID: 39872399 PMC: 11749639. DOI: 10.1093/lifemedi/lnae010.
Current Approaches for Genetic Manipulation of spp.-Key Bacteria for Biotechnology and Environment.
Krysenko S BioTech (Basel). 2025; 14(1.
PMID: 39846552 PMC: 11755657. DOI: 10.3390/biotech14010003.
Optimizing genome editing efficiency in via a CRISPR/Cas9n-mediated editing system.
Wu Y, Jin H, Yu Q, Wei Z, Zhu J, Qiu X Appl Environ Microbiol. 2025; 91(2):e0195324.
PMID: 39840981 PMC: 11837490. DOI: 10.1128/aem.01953-24.
Identification of multiple regulatory genes involved in TGase production in DSM 40587.
Liu X, Wang D, Zhang Y, Zhuang X, Bai L Eng Microbiol. 2024; 3(4):100098.
PMID: 39628909 PMC: 11611014. DOI: 10.1016/j.engmic.2023.100098.